免疫调节 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-19. Anything still debated is marked as such rather than presented as settled.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
=== EC 2.7.7: Nucleotidyltransferases === EC 2.7.7.1: nicotinamide-nucleotide adenylyltransferase EC 2.7.7.2: FAD synthase EC 2.7.7.3: pantetheine-phosphate adenylyltransferase EC 2.7.7.4: sulfate adenylyltransferase EC 2.7.7.5: sulfate adenylyltransferase (ADP) EC 2.7.7.6: DNA-directed RNA polymerase EC 2.7.7.7: DNA-directed DNA polymerase EC 2.7.7.8: polyribonucleotide nucleotidyltransferase EC 2.7.7.9: UTP—glucose-1-phosphate uridylyltransferase EC 2.7.7.10: UTP—hexose-1-phosphate uridylyltransferase EC 2.7.7.11: UTP—xylose-1-phosphate uridylyltransferase EC 2.7.7.12: UDP-glucose—hexose-1-phosphate uridylyltransferase EC 2.7.7.13: mannose-1-phosphate guanylyltransferase EC 2.7.7.14: ethanolamine-phosphate cytidylyltransferase EC 2.7.7.15: choline-phosphate cytidylyltransferase EC 2.7.7.16: Now EC 4.6.1.18, pancreatic ribonuclease EC 2.7.7.17: Now EC 4.6.1.19, ribonuclease T2 EC 2.7.7.18: nicotinate-nucleotide adenylyltransferase EC 2.7.7.19: polynucleotide adenylyltransferase EC 2.7.7.20: deleted (identical with EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.21: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.22: mannose-1-phosphate guanylyltransferase (GDP) EC 2.7.7.23: UDP-N-acetylglucosamine diphosphorylase EC 2.7.7.24: glucose-1-phosphate thymidylyltransferase EC 2.7.7.25: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.26: Now EC 4.6.1.24, ribonuclease T1 EC 2.7.7.27: glucose-1-phosphate adenylyltransferase EC 2.7.7.28: nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.29: identical to EC 2.7.7.28, nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.30: fucose-1-phosphate guanylyltransferase EC 2.7.7.31: DNA nucleotidylexotransferase EC 2.7.7.32: galactose-1-phosphate thymidylyltransferase EC 2.7.7.33: glucose-1-phosphate cytidylyltransferase EC 2.7.7.34: glucose-1-phosphate guanylyltransferase EC 2.7.7.35: ribose-5-phosphate adenylyltransferase EC 2.7.7.36: aldose-1-phosphate adenylyltransferase EC 2.7.7.37: aldose-1-phosphate nucleotidyltransferase EC 2.7.7.38: 3-deoxy-manno-octulosonate cytidylyltransferase EC 2.7.7.39: glycerol-3-phosphate cytidylyltransferase EC 2.7.7.40: D-ribitol-5-phosphate cytidylyltransferase EC 2.7.7.41: phosphatidate cytidylyltransferase EC 2.7.7.42: [glutamine synthetase] adenylyltransferase EC 2.7.7.43: N-acylneuraminate cytidylyltransferase EC 2.7.7.44: glucuronate-1-phosphate uridylyltransferase EC 2.7.7.45: guanosine-triphosphate guanylyltransferase EC 2.7.7.46: gentamicin 2′′-nucleotidyltransferase EC 2.7.7.47: streptomycin 3′′-adenylyltransferase EC 2.7.7.48: RNA-directed RNA polymerase EC 2.7.7.49: RNA-directed DNA polymerase EC 2.7.7.50: mRNA guanylyltransferase EC 2.7.7.51: adenylylsulfate—ammonia adenylyltransferase EC 2.7.7.52: RNA uridylyltransferase EC 2.7.7.53: ATP adenylyltransferase EC 2.7.7.54: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.55: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.56: tRNA nucleotidyltransferase EC 2.7.7.57: N-methylphosphoethanolamine cytidylyltransferase EC 2.7.7.58: Now included in EC 6.2.1.71, 2,3-dihydroxybenzoate[aryl-carrier protein] ligase EC 2.7.7.59: [protein-PII] uridylyltransferase EC 2.7.7.60: 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase EC 2.7.7.61: citrate lyase holo-[acyl-carrier protein] synthase EC 2.7.7.62: adenosylcobinamide-phosphate guanylyltransferase EC 2.7.7.63: Now EC 6.3.1.20, lipoate—protein ligase EC 2.7.7.64: UTP-monosaccharide-1-phosphate uridylyltransferase EC 2.7.7.65: diguanylate cyclase EC 2.7.7.66: malonate decarboxylase holo-[acyl-carrier protein] synthase EC 2.7.7.67: CDP-2,3-bis-(O-geranylgeranyl)-sn-glycerol synthase EC 2.7.7.68: 2-phospho-L-lactate guanylyltransferase EC 2.7.7.69: GDP-L-galactose/GDP-D-glucose: hexose 1-phosphate guanylyltransferase EC 2.7.7.70: D-glycero-β-D-manno-heptose 1-phosphate adenylyltransferase EC 2.7.7.71: D-glycero-α-D-manno-heptose 1-phosphate guanylyltransferase EC 2.7.7.72: CCA tRNA nucleotidyltransferase EC 2.7.7.73: sulfur carrier protein ThiS adenylyltransferase EC 2.7.7.74: 1L-myo-inositol 1-phosphate cytidylyltransferase EC 2.7.7.75: molybdopterin adenylyltransferase EC 2.7.7.76: molybdenum cofactor cytidylyltransferase EC 2.7.7.77: molybdenum cofactor guanylyltransferase EC 2.7.7.78: GDP-D-glucose phosphorylase EC 2.7.7.79: tRNAHis guanylyltransferase EC 2.7.7.80: molybdopterin-synthase adenylyltransferase EC 2.7.7.81: pseudaminic acid cytidylyltransferase EC 2.7.7.82: CMP-N,N′-diacetyllegionaminic acid synthase EC 2.7.7.83: UDP-N-acetylgalactosamine diphosphorylase EC 2.7.7.84: diadenylate cyclase EC 2.7.7.85: 2′-5′ oligoadenylate synthase EC 2.7.7.86: cyclic GMP-AMP synthase EC 2.7.7.87: L-threonylcarbamoyladenylate synthase EC 2.7.7.88: GDP polyribonucleotidyltransferase EC 2.7.7.89: [glutamine synthetase]-adenylyl-L-tyrosine phosphorylase EC 2.7.7.90: 8-amino-3,8-dideoxy-''manno''-octulosonate cytidylyltransferase EC 2.7.7.91: valienol-1-phosphate guanylyltransferase EC 2.7.7.92: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate cytidylyltransferase EC 2.7.7.93: phosphonoformate cytidylyltransferase EC 2.7.7.94: Now EC 6.2.1.51, 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 2.7.7.95: Now EC 6.2.1.49, long-chain fatty acid adenylyltransferase FadD28 EC 2.7.7.96: ADP-D-ribose pyrophosphorylase EC 2.7.7.97: 3-hydroxy-4-methylanthranilate adenylyltransferase EC 2.7.7.98: Now EC 6.2.1.50, 4-hydroxybenzoate adenylyltransferase FadD22 EC 2.7.7.99: N-acetyl-α-D-muramate 1-phosphate uridylyltransferase EC 2.7.7.100: SAMP-activating enzyme EC 2.7.7.101: DNA primase DnaG EC 2.7.7.102: DNA primase AEP EC 2.7.7.103: L-glutamine-phosphate cytidylyltransferase EC 2.7.7.104: 2-hydroxyethylphosphonate cytidylyltransferase EC 2.7.7.105: phospho''enol''pyruvate guanylyltransferase EC 2.7.7.106: 3-phospho-D-glycerate guanylyltransferase
=== Background and education === Galloway was born in Dundee, Scotland on 16 August 1954, to George Galloway Sr., a Scottish trade unionist, and Sheila O'Reilly, a Scot of Irish descent. Initially raised in Lochee, Dundee, he has described himself as "born in an attic in a slum tenement in the Irish quarter of Dundee, which is known as Tipperary". His father began as an electrician, before studying a degree to become an electromechanical engineer at NCR. After being made redundant, he retrained as a teacher. His mother was a cleaner, and then a factory worker. According to Galloway, his father was patriotic, while his mother had Irish nationalist sympathies, and was critical of perceived British pretensions in the world. He took his mother's side in arguments, and has been a long-time supporter of Sinn Féin and Irish reunification. David Morley, his biographer, has written that people who knew both father and son have said that they had Marxist opinions common in the local Labour Party movement of the time. Galloway grew up in Charleston, Dundee, and attended Charleston Primary and then Harris Academy, in the city's West End, an academically selective and non-denominational state school, which became comprehensive in 1973. Galloway played for the school football team as well as for West End United U12s, Lochee Boys Club U16s and St Columba's U18s.
Manifold are thy shapings, Providence! / Many a hopeless matter gods arrange / What we expected never came to pass / What we did not expect the gods brought to bear / So have things gone, this whole experience through! This deliberate murder of her children by Medea appears to be Euripides' invention, although some scholars believe Neophron created this alternate tradition. Her filicide would go on to become the standard for later writers. Pausanias, writing in the late 2nd century AD, records five different versions of what happened to Medea's children after reporting that he has seen a monument for them while traveling in Corinth.
A quantity is subject to exponential decay if it decreases at a rate proportional to its current value. Symbolically, this process can be expressed by the following differential equation, where N is the quantity and λ (lambda) is a positive rate called the exponential decay constant, disintegration constant, rate constant, or transformation constant:
Both the δDs of sea water and the fractionations associated with hyptophyte biochemistry (εbio) are fairly well understood, so alkenones can be readily used to observe the secondary effect of salinity on δD. There is a well established positive linear correlation between salinity and εl/w, on the order of a ~3‰ change in fractionation per salinity unit. Hypothesized mechanisms for this effect include enrichment of D in intracellular water due to reduced exchange with extracellular water at higher salinity, removal of H from intracellular water due to increased production of solutes to maintain osmotic pressure at higher salinity, and lower haptophyte growth rates at higher salinity Alkenone δDs have been used successfully to reconstruct past salinity changes in the Mediterranean Sea, Black Sea, Panama Basin, and Mozambique Channel. As an extension of salinity, this data was also used to draw further conclusions about ancient environments, such as ancient freshwater flooding events, and the evolution of plankton in response to environmental changes
Sources: en.wikipedia.org
=== Enzyme regulation === The activity of some enzymes is regulated by ADP-ribosylation. For instance, the activity of Rodospirillum rubrum di-nitrogenase-reductase is turned off by ADP-ribosylation of an arginine residue, and reactivated by the removal of the ADP-ribosyl group.
In chemistry and physics, cohesion (from Latin cohaesiō 'cohesion, unity'), also called cohesive attraction or cohesive force, is the action or property of like molecules sticking together, being mutually attractive. It is an intrinsic property of a substance that is caused by the shape and structure of its molecules, which makes the distribution of surrounding electrons irregular when molecules get close to one another, creating an electrical attraction that can maintain a macroscopic structure such as a water drop. Cohesion allows for surface tension, creating a "solid-like" state upon which light-weight or low-density materials can be placed. Water, for example, is strongly cohesive as each molecule may make four hydrogen bonds to other water molecules in a tetrahedral configuration. This results in a relatively strong Coulomb force between molecules. In simple terms, the polarity (a state in which a molecule is oppositely charged on its poles) of water molecules allows them to be attracted to each other. The polarity is due to the electronegativity of the atom of oxygen: oxygen is more electronegative than the atoms of hydrogen, so the electrons they share through the covalent bonds are more often close to oxygen rather than hydrogen. These are called polar covalent bonds, covalent bonds between atoms that thus become oppositely charged. In the case of a water molecule, the hydrogen atoms carry positive charges while the oxygen atom has a negative charge.
Follitropin subunit beta also known as follicle-stimulating hormone beta subunit (FSH-B) is a protein that in humans is encoded by the FSHB gene. Alternative splicing results in two transcript variants encoding the same protein.
In March 2016, the International Narcotics Control Board stated that the UN's international drug treaties do not mandate a "war on drugs" and that the choice is not between "'militarized' drug law enforcement on one hand and the legalization of non-medical use of drugs on the other", health and welfare should be the focus of drug policy. That April, the UN General Assembly Special Session (UNGASS) on the "World Drug Problem" was held. The Wall Street Journal assessed the attendees' positions as "somewhat" in two camps: "Some European and South American countries as well as the U.S. favored softer approaches. Eastern countries such as China and Russia and most Muslim nations like Iran, Indonesia and Pakistan remained staunchly opposed." The outcome document recommended treatment, prevention and other public health measures, and committed to "intensifying our efforts to prevent and counter" drug production and trafficking, through, "inter alia, more effective drug-related crime prevention and law enforcement measures." Under President Donald Trump (2017–2021), Attorney General Jeff Sessions reversed the previous Justice Department's cannabis policies, rescinding the Cole Memo that deferred federal enforcement in states where cannabis had been legalized He instructed federal prosecutors to "charge and pursue the most serious, readily provable offense" in drug cases, regardless of whether mandatory minimum sentences applied, which could trigger mandatory minimums for lower-level charges.
=== Alternatives to approved sources === Gray market sellers offer unauthorized products they claim are GLP-1 agonists. Some buyers turn to unauthorized retailers if they cannot afford the name-brand drug. Buyers face risks due to counterfeit or substandard drugs. In the United States, compounding pharmacies may sell custom-made versions of a drug if there is a declared shortage and they obtain the active pharmaceutical ingredient from an FDA-approved facility. The FDA declared shortages of injectable versions of semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide in 2022. The tirzepatide shortage ended in 2024. Al Carter, executive director of the National Association of Boards of Pharmacy, a trade organization for pharmacy regulators, estimated that 95% of online compounding pharmacies were operating illegally in 2024. As of January 2026, there were up to 1.5 million users of compounded GLP-1 receptor agonist drugs in the U.S., according to Novo Nordisk CEO Mike Doustdar. He decried the practice of selling what he called "unsafe, knock-off products" while conceding that compounding pharmacies capture price-sensitive consumers in a way that his company, with its more expensive branded offerings, cannot.
Sources: en.wikipedia.org
https://doi.org/10.1016/j.cell.2024.10.042 Schat, K. A., Kaspers, B., & Kaiser, P. (2014). Structure of the Avian Lymphoid System. In I. Olah, N. Nagy & L. Vervelde (Eds.), Avian Immunology (2nd ed., pp. 11-44). Academic Press.
They can sedate patients receiving mechanical ventilation or those in extreme distress. Caution is exercised in this situation due to the risk of respiratory depression, and it is recommended that benzodiazepine overdose treatment facilities should be available. They have also been found to increase the likelihood of later PTSD after people have been removed from ventilators. Benzodiazepines are indicated in the management of breathlessness (shortness of breath) in advanced diseases, in particular where other treatments have failed to adequately control symptoms. Benzodiazepines are effective as medication given a couple of hours before surgery to relieve anxiety. They also produce amnesia, which can be useful, as patients may not remember unpleasantness from the procedure. They are also used in patients with dental phobia as well as some ophthalmic procedures like refractive surgery; although such use is controversial and only recommended for those who are very anxious. Midazolam is the most commonly prescribed for this use because of its strong sedative actions and fast recovery time, as well as its water solubility, which reduces pain upon injection. Diazepam and lorazepam are sometimes used. Lorazepam has particularly marked amnesic properties that may make it more effective when amnesia is the desired effect. Benzodiazepines are well known for their strong muscle-relaxing properties and can be useful in the treatment of muscle spasms, although tolerance often develops to their muscle-relaxant effects.
=== Algeria === Algeria is an oil and natural gas producer, and one of the European Union's largest suppliers of LNG. It has entered talks with Spain and Italy, as well as fielding enquiries from other countries, including Vietnam. It could benefit economically.
Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and primary sclerosing cholangitis (PSC). It is being investigated for use alone or in combination with firsocostat, selonsertib, or semaglutide. In rat models and human clinical trials of NASH it has been shown to reduce fibrosis and steatosis, and in human clinical trials of PSC it improved cholestasis and reduced markers of liver injury. It is being developed by the pharmaceutical company Gilead Sciences.
=== Oxidation === Oxidation can occur both at sulfur, giving a thiophene S-oxide, as well as at the 2,3-double bond, giving the thiophene 2,3-epoxide, followed by subsequent NIH shift rearrangement. Oxidation with trifluoroperacetic acid demonstrates both reaction pathways. The major pathway forms the S-oxide as an intermediate, which undergoes subsequent Diels-Alder-type dimerisation and further oxidation, forming a mixture of sulfoxide and sulfone products with a combined yield of 83% (based on NMR evidence):
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.